The patient, reportedly not recommended for bariatric surgery due to age and existing conditions, raises questions about eligibility for the trial of retatrutide. Experts highlight the oddities of the expanded access notice, which lacked typical qualifying information. Richard Klein, a veteran of the FDA's program, emphasized the confusion surrounding the listing, noting only informed individuals may uncover its details.
The FDA's support for expanded access allows patients with serious conditions access to investigational treatments, yet the practice of granting access to one individual rather than a group is unusual. Officials from both the White House and Health and Human Services did not confirm or deny Trump's involvement as a patient, but a statement reiterated the FDA’s case-by-case review process for such requests. Lilly Pharmaceuticals, involved in the drug's trial, refrained from commenting on specific inquiries about Trump.